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Pulmonary surfactant is a lipid-protein complex that coats the interior of the 
alveoli and enables the lungs to function properly. Upon its synthesis, lung 
surfactant adsorbs at the interface between the air and the hypophase, a 
capillary aqueous layer covering the alveoli. By lowering and modulating 
surface tension during breathing, lung surfactant reduces respiratory work of 
expansion, and stabilises alveoli against collapse during expiration. 
Pulmonary surfactant deficiency, or dysfunction, contributes to several 
respiratory pathologies, such as infant respiratory distress syndrome (IRDS) in 
premature neonates, and acute respiratory distress syndrome (ARDS) in 
children and adults. The main clinical exogenous surfactants currently in use to 
treat some of these pathologies are essentially organic extracts obtained from 
animal lungs. Although very efficient, natural surfactants bear serious defects: i) 
they could vary in composition from batch to batch; ii) their production 
involves relatively high costs, and sources are limited; and iii) they carry a 
potential risk of transmission of animal infectious agents and the possibility of 
immunological reaction. All these caveats justify the necessity for a highly 
controlled synthetic material. 
In the present review the efforts aimed at new surfactant development, 
including the modification of existing exogenous surfactants by adding 
molecules that can enhance their activity, and the progress achieved in the 
production of completely new preparations, are discussed. 
 
Abbreviations 
ARDS: acute respiratory distress syndrome; DPPC: 1,2-dipalmitoyl 
phosphatidylcholine; IRDS: infant respiratory distress syndrome; LPC: 
lysophosphatidylcholine; POPG: palmitoyl oleyl phosphatidylglycerol; rSP-C: 
recombinant surfactant protein C; 
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Pulmonary surfactant function and dysfunction 
The respiratory surface of lungs constitutes the largest area of the human body 
exposed to the environment. Efficient gas exchange requires a large enough 
surface to be continuously exposed to air while minimising the barriers for 
oxygen and carbon dioxide to diffuse between air and the blood compartment 
[1]. At the same time, a selection of combined defence mechanisms is required 
to help keep such an essentially exposed area sterile of potential pathogenic 
microorganisms. Pulmonary surfactant, a lipid-protein complex produced by 
the alveolar epithelium of lungs, has been optimised to coordinate two main 
activities through natural evolution. On the one hand, it stabilises the 
respiratory surface against physical forces, therefore minimising the work 
required to maintain the large respiratory surface open to air [2-4]. On the other 
hand, pulmonary surfactant contains elements responsible for establishing a 
primary innate antipathogenic barrier, essential to ensure an intrinsically low 
pathogen load in the absence of induced defence mechanisms [5]. Extensive 
research in the last few decades has revealed some of the molecular 
mechanisms involved in pulmonary surfactant action. However, the manner in 
which both the biophysical and defence activities are intermingled and 
coordinately modulated in the alveolar spaces is now only beginning to be 
envisioned.  
Pulmonary surfactant is composed of approximately 90% lipids and 8-
10% proteins, although only around 5% are specific surfactant-associated 
polypeptides [6,7]. Phospholipids constitute around 80% per mass of surfactant 
and are the main surface active molecules, able to form interfacial films capable 
of reducing the surface tension at the alveolar air-liquid interface until values 
close to 0 mN/m, which are reached at the end of expiration, a strict 
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requirement to prevent atelectasis and alveolar collapse [3]. Surfactant 
phospholipids assemble in the type II pneumocytes of the lung epithelium in 
the form of bilayered membranes. In the absence of surfactant proteins, 
phospholipid membranes have a very poor tendency to adsorb at the air-liquid 
interface as the hydrophobic chains of the lipid molecules would be transiently 
exposed to water on their way to the air phase from the bilayers. A small 
percentage, around 1-2% of surfactant per mass, of two evolutionarily 
conserved proteins, namely SP-B and SP-C, is sufficient to catalyse the rapid 
transfer of surface active phospholipids into the interface to efficiently form the 
operative surfactant film [4,8]. The lack of both proteins at birth, when air 
respiration has to be established, produces a lethal and irreversible respiratory 
failure as a consequence of the impossibility to maintain the lungs open [9], 
either  in genetically manipulated animal models or in patients with inherited 
genetic deficiencies [10]. Another two proteins in the surfactant, known as SP-A 
and SP-D, form large macromolecular assemblies and they are capable of 
binding to the surface of bacteria, viruses and fungi to favour their clearance 
from the airways [5,11].  
The lack of a functional pulmonary surfactant in the immature lungs of 
preterm babies leads to IRDS, which was the major cause of mortality and 
morbidity in neonates before supplementation with exogenous surfactant was 
established as a therapeutic technique [12]. Today, babies at risk of developing 
IRDS are routinely treated with an exogenous surfactant material that helps to 
open and maintain their lungs open until they are able to synthesise their own 
endogenous surfactant [13,14]. Implementation of the exogenous surfactant 
therapeutic procedures was probably a major contribution to the sharp drop in 
infant mortality, which took place in the eighties. Most surfactant preparations 
presently used in neonatology services are obtained from extracts of animal 
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surfactants, usually of a bovine or porcine origin [13,15]. They consist of the full 
hydrophobic fraction of surfactant, containing most of the lipids and variable 
amounts of the surface-active hydrophobic proteins SP-B and SP-C. The 
production methodologies of these different natural surfactant preparations, as 
well as their variable supplementation with supposedly beneficial components, 
give rise to differences in composition and biophysical activity, which have 
been recently reviewed elsewhere [16]. 
Another pathology related to pulmonary surfactant dysfunction is  
ARDS associated with acute lung injury (ALI) [17]. As a secondary consequence 
of several types of lung injury, inflammation and disruption of the alveolar-
capillary barrier lead to the leakage of serum components into the airspaces, 
which are responsible for a severe inactivation of the biophysical activities of 
the surfactant complex [18]. Several trials have addressed the potential 
treatment of ARDS with exogenous surfactant in animal models and patients, 
but with limited success [19,20]. The limited availability of the amounts of 
surfactant required to treat adults, and the high susceptibility of present 
exogenous surfactants to inhibition by plasma components, are major caveats 
that preclude further developments of exogenous surfactant therapies directed 
to treat ARDS. A major objective of the research in this field is, therefore, the 
development of a new generation of therapeutic surfactants, made from 
human-like components, produced in enough quantity and at a reasonable cost, 
and which are intrinsically resistant to inactivation. The present review 
summarises recent developments which survey the potential of certain lipid-
protein combinations containing either synthetic peptides or recombinant 
proteins designed to mimic human surfactant complexes as a basis for future 
surfactant therapies in babies and adults.  
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The lipid moiety of pulmonary surfactant 
For a surfactant preparation to be effective enough to stabilise the respiratory 
surface throughout successive compression-expansion cycles, it must fulfil three 
main activities: i) the promotion of a very rapid formation of surface active 
films at the air-liquid interface, mainly during expansion at inspiration; ii) a 
reduction of the surface tension at the interface to very low values, around or 
below 1 mN/m, upon compression at the end of expiration, but in a manner 
progressively dependent on the reduction of volume, to avoid that small alveoli 
collapse into larger ones; and iii) efficient re-spreading upon the expansion of 
the interface, to re-establish the competent state of the film, which is able to 
produce the lowest tensions throughout multiple cycles [4].  
Early studies on the biophysical behaviour of pulmonary surfactant 
components in surface balances already established that the phospholipid 
fraction of surfactant is the main responsible to form stable surface active films 
able to reach very low surface tension upon compression. Those seminal studies 
also provided the evidences for the concept that saturated phospholipid species 
such as dipalmitoylphosphatidylcholine (DPPC), which is in a gel-like state at 
physiological temperatures, are the only ones with the potential to be packed to 
a very high density at the interface, which is required to produce the lowest 
tensions –the largest interfacial water depletion– upon compression. Since then, 
detailed physico-chemical studies of different simplified lipid and lipid-protein 
surfactant models have concluded that an appropriate lipid composition 
containing a fair proportion of saturated phospholipid species is essential for 
films to reach low enough surface tensions [6,7]. Natural pulmonary surfactant 
contains around 40% DPPC, which, by itself, is able to reach very low surface 
tensions when films made of this lipid are compressed at physiological 
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temperatures. However, lipid species such as DPPC are extremely inefficient at 
adsorbing into the interface. The presence of some unsaturated phospholipid 
species and cholesterol contributes to fluidify surfactant membranes and thus 
improve their dynamical behaviour. 
Before the discovery of the hydrophobic surfactant proteins, some 
protein-free preparations were designed and assessed as potential therapeutic 
agents. Exosurf! consisted mainly of DPPC and some amounts of cetyl alcohol 
and tyloxapol as spreading agents to facilitate interfacial adsorption, but its 
efficacy was always significantly inferior to those surfactant preparations 
containing proteins [21]. Other pure lipidic preparations incorporated also some 
proportions of anionic phospholipids [22] and other lipid additives have been 
assessed as potential agents to improve DPPC dynamics [23], but the idea that 
an efficient therapeutic surfactant could be designed in the absence of surface 
active proteins was abandoned soon. In fact, is the action of proteins SP-B and 
SP-C that greatly facilitates the rapid movement of surface-active lipids 
between membranes and the interface and helps to re-spread the compressed 
states of the films during subsequent cycling [8,24]. For this reason, this review 
will pay special attention to current ideas on the design and production of 
hydrophobic surfactant protein analogs to develop new artificial surfactants. 
Still, some concepts can be discussed on how an efficient clinical 
surfactant can be optimized from the point of view of the lipid composition. 
There is no discussion that an efficient surfactant requires enough proportion of 
DPPC and some amount of the most usual anionic phospholipid in surfactant, 
phosphatidylglycerol (PG). This charged phospholipid has shown to provide 
specific interactions with the hydrophobic proteins, especially SP-B, 
contributing to optimize their biophysical activity [25,26]. A classical and 
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simple lipid mixture, which is still used as the basis of some of the synthetic 
surfactants presently under development, consists of the mixture 
DPPC/palmitoyloleoyl PG (POPG), 70:30 (w/w). This simple system provides 
excellent in vitro and in vivo properties when reconstituted in the presence of 
some proportions of native proteins SP-B [27] and/or SP-C [28-30] or selected 
synthetic peptides [i.e. [31-33], and has been used as the basis of surfactant 
preparations such as Surfaxin [34-36], Venticute [37-41] or SP-C33 [42] (see 
below). However, the ratio of saturated/unsaturated phospholipids and the 
fraction of charged species are both markedly higher in this mixture than in 
natural surfactant. Animal-derived surfactants such as Curosurf, Alveofact or 
BLES contain DPPC and PG proportions much closer to the ones in native 
surfactant, in the order of 40-50 and 10-15%, respectively [16]. Interestingly 
Survanta, which is also obtained from a bovine surfactant extract, is 
supplemented with additional DPPC to reach proportions also in the order of 
70% by mass.  
The inclusion of significant proportions of free fatty acids as an additive 
in clinical surfactants deserves some discussion. Minor amounts of fatty acids 
such as palmitate are detected in the composition of native pulmonary 
surfactant, but in much less proportion than incorporated in preparations such 
as Survanta, Surfaxin and Venticute. The rational for this incorporation comes 
from in vitro tests showing that the presence of palmitic acid improves 
substantially the stability of interfacial films, which are thus able to maintain 
very low surface tensions when repeatedly compressed [43,44]. The problem is 
that these palmitic-containing mixtures reach and maintain low surface tensions 
at the cost of bearing a high viscosity, both as lipid/protein or lipid/peptide 
suspensions and as interfacial films. One has to bear in mind that composition 
in native surfactant is optimized in such a way that it stably sustains low 
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tensions with relatively low viscosity, which facilitates spreading and 
redistribution along the smallest airways. Important elements that have 
probably to be considered to optimize further the composition of clinical 
surfactants include a proper amount of surfactant protein SP-B, minor but 
significant proportions of alkyl phospholipids and enough but not too much 
cholesterol. The importance of the presence of SP-B or SP-B mimics will be 
discussed later. Presence in surfactant of some amounts of plasmalogens and 
other alkyl- and alkenyl-phospholipids has been consistently correlated with 
optimal surfactant dynamics and low viscosity [45,46]. Finally, the importance 
for the structure and the behaviour of surfactant of a proper proportion of 
cholesterol is only starting to be envisaged in the last few years. In spite that 
cholesterol is present in proportions in the order of 5-10% of natural surfactants, 
it is systematically removed from all the clinical surfactant preparations used 
today, either synthetic or from animal origin. The reason is that cholesterol 
showed to impair surface activity in simple lipid systems tested in surface 
balances [47]. However, cholesterol is well recognized as a component that 
provides mechanical stability to cell membranes [48] and an important 
structural element to modulate their lateral structure, including segregation of 
specialized domains such as lipid rafts [49,50]. Recent results have shown that 
physiological proportions of cholesterol modulate the lateral organization and 
distribution of proteins and lipids in pulmonary surfactant membranes [51] and 
films [52,53], as well as the dynamical behaviour of surfactant films subjected to 
compression-expansion cycling [54]. Presence of cholesterol could be 
particularly important to permit surfactant films to reach and sustain the lowest 
surface tensions at 100% humidity [55], a condition thought to exist in the 
alveolar spaces but poorly reproduced in in vitro models. Excess of cholesterol 
has been however associated with a deleterious activity in surfactant from 
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injured lungs [56,57], although it is not clear whether that exacerbated amounts 
of the steroid are a cause or a consequence of physiological responses to a 
partially inefficient respiratory function. We believe that there is still much 
room for optimization of the composition in future clinical surfactants, strictly 
attending to the lipid moiety, and that further understanding will come from 
the systematic study of the role of the full compositional complexity of native 
pulmonary surfactant.  
 
Structure-function relationships of SP-B 
The pulmonary surfactant protein B (SP-B) is the most important protein for 
surfactant activity to maintain lung airspaces open. Recent studies with 
genetically-modified animals, in which the expression of SP-B could be 
switched on or off by the presence or absence, respectively, of a conditioning 
inductor, have shown that the presence of a threshold proportion of SP-B is 
strictly required in surfactant for animals to sustain the proper respiratory 
dynamics [30,58].  A reduction of the level of SP-B below that threshold 
correlates with the rapid development of a severe respiratory failure, even in 
the presence of proper levels of the other hydrophobic protein, SP-C.  This 
failure could be completely reversed upon reactivation of SP-B gene expression.  
SP-B is co-isolated with lipids from the hydrophobic fraction of 
surfactant in the form of a covalently linked dimer of two 79-residue 
polypeptides [59]. The mature form of SP-B assembled and secreted into the 
alveolar spaces as part of the surfactant complexes, originates from the 
proteolytic processing of a much larger precursor of 381 amino acids. This 
maturation occurs in several steps throughout the exocytic pathway from the 
endoplasmic reticulum, where the protein is synthesised, through the Golgi and 
multivesicular bodies, until it appears in the lamellar bodies, the organelles 
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where surfactant membranes finally assemble and are stored until secretion 
[60]. The final SP-B fold contains three intramolecular disulfide bonds (Fig. 1), 
and is thought to be homologous to the structure of saposin-like proteins [61], a 
family of membrane-active proteins including sphingolipid activator proteins, 
that is, saposins themselves [62-64] [65] and cytotoxins such as the amoebapore 
[66], NK-lysine [67] and granulysine [68]. The structure of some of these 
proteins has, in most cases, been solved in a membrane-free state. However, a 
molecular structure of SP-B, the only member of the saposin family that is 
permanently associated with membranes, is still not available despite the fact 
that some molecular modelling efforts have been reported [69,70]. Numerous 
studies have approached the analysis of structural determinants in SP-B by 
means of indirect techniques such as circular dichroism [71,72] [73], 
fluorescence [74] or infrared spectroscopies [75,76], or electron spin resonance 
(ESR) [77]. The protein structure is dominated by a 40-50% "-helix, predicted to 
be in the form of amphipathic helical segments with well-defined polar and 
non-polar faces. These helices would promote an orientated interaction of SP-B, 
where the average axis of its helical segments is parallel to the plane defined by 
the surface of surfactant phospholipid bilayers and interfacial films [76]. This 
peripheral disposition could be important for the property of SP-B to stabilise 
surfactant film compressed states [78]. The protein possesses a net positive 
charge of +7 at a physiological pH, which would facilitate its selective 
interaction with the fraction of negatively charged phospholipids in surfactants, 
mainly phosphatidylglycerol [26].  
Different techniques have revealed that the interaction of SP-B with 
membranes promotes a significant perturbation of lipid packing and a strong 
alteration of their permeability barrier. SP-B thus induces leakage of the 
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contents from liposomes as well as lipid vesicle aggregation and fusion [79,80] 
[81]. SP-B-promoted perturbation of membrane structure could also be 
responsible for the ability of the protein to catalyse the exchange of 
phospholipids between membranes and to accelerate the transfer of surface-
active lipid species from bilayers into air-liquid interfaces [82] [78,83]. These SP-
B-promoted membrane-perturbing activities have been directly mapped to the 
amphipathic helical segments of the protein, with some segments located near 
the N-terminal and C-terminal ends being the most active [30,84]. Accordingly, 
the present working model proposes that the biophysical activity of SP-B is 
mainly due to a more or less deep penetration of the hydrophobic faces of 
certain amphipathic helical segments into the hydrophobic core of surfactant 
bilayers and interfacial films. The perturbations produced on lipid packing by 
the insertion of the SP-B helices would mediate membrane destabilisation and 
inter-membrane phospholipid transfer. The extent of penetration of SP-B into 
phospholipid membranes is, however, a matter of debate [72,82,85], and 
probably suggests that the protein could adopt different positions depending 
on the method used to reconstitute lipid-protein complexes [80]. The real 
physiological significance of these different SP-B/membrane organizations is 
still to be properly explored and probably requires a more extensive study of 
the orientation/organization of SP-B in native surfactant complexes under non-
denaturing conditions.  
It has also been proposed that SP-B could participate in stabilising the 
intermediates involved in the transfer of phospholipids between lipid layers 
[86]. In this sense, the capacity of SP-B, as a dimer or even as a higher order 
oligomer, to simultaneously interact with neighbouring phospholipid surfaces 
could be crucial to facilitate lipid exchange. When passing between surfactant 
layers, phospholipids could transiently associate with potential SP-B-based 
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inter-membrane bridges, which would prevent their unfavorable exposure to 
the aqueous environment. 
The amphipathic helical motifs, however, are necessary but not sufficient 
for SP-B to manifest its optimal biophysical activities in surfactant preparations. 
Recently, it has been demonstrated that the protein needs a high enough 
affinity to insert into polar/non-polar interfaces in order to produce and 
maintain the lowest surface tensions achieved in surfactant films subjected to 
rapid compression-expansion dynamics. This affinity is critically dependent on 
the integrity of a cluster of aromatic residues located near the N-terminal end of 
the protein, and especially on the single tryptophan residue in the sequence of 
SP-B (Fig. 1) [30]. This tryptophan is strictly conserved in all the sequences of 
SP-B known to date, and could lead a very rapid insertion of the protein into 
the phospholipid-loaded air-liquid interface during the brief periods of time 
that the film is under expansion. Substituting the tryptophan for another amino 
acid with less interfacial affinity leads to a substantially reduced ability of the 
protein to reinsert into the interface during successive compression cycles, and 
a partial inefficiency to sustain proper replenishment of the interfacial film with 
the surface-active molecules lost during the compression moiety of the 
respiratory cycle [4]. 
The ability of SP-B to perturb phospholipid membranes has also been 
related to a potential antibiotic activity, which may also be mediated by an SP-
B-promoted alteration of the permeability barrier of bacterial envelopes [87,88]. 
These microbicidal activities of SP-B have been mainly reported in vitro and no 
clear notion exists as to whether SP-B might also have a potential function in the 
innate defence activities of pulmonary surfactant in the lung airspaces. 
 
SP-B-related synthetic surfactants  
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The structural complexity of SP-B, including its high hydrophobicity and the 
presence of both intra- and inter-molecular disulfides (Fig. 2), has meant that, so 
far, it has been impossible to obtain a recombinant version of the human protein 
for potential use in the production of SP-B-based clinical surfactants. Therefore, 
attempts to produce artificial surfactants, including SP-B with human sequence, 
have been limited to the design and characterisation of peptides that mimic SP-
B-like activities. A recent study has demonstrated that SP-B retains most of the 
properties required to promote the formation and stability of interfacial films, 
even after its unfolding, and the reduction and alkylation of its cysteine 
residues [29]. This means that the amino acid sequence of the protein possesses 
intrinsic surface-active determinants beyond the behavior of the native fold, 
and provides the basis to think that these potentially functional determinants 
could be exploited if properly mimicked in simpler peptides. 
Several studies have attempted to make use of the connection between 
protein-promoted surface activity and the membrane-perturbing properties of 
amphipathic helical segments by exploring the potential utility of different 
amphipathic helical peptides as potential additives in surfactant preparations. 
Admixtures of DPPC and variable proportions of these simple peptides had 
enough surface activity to mimic pulmonary surfactant in animal models of 
surfactant deficiency [89-92]. This evidence provides support for the idea that a 
clinical surfactant could, in principle, be produced by a proper combination of 
lipids and synthetic peptides. Careful analysis of the SP-B sequence 
determinants for surface activity revealed that a peptide synthesised from the 
last 20 amino acids of SP-B was able to mimic the ability of SP-B to sustain very 
low surface tensions during compression-expansion dynamics [82,84]. These 
experiments are the origin of the design of KL4, the first SP-B-inspired synthetic 
peptide incorporated in a surfactant preparation that has reached clinical trials 
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[34-36]. This peptide, which simulates the sequence pattern of 
cationic/hydrophobic residues found in the C-terminal segment of SP-B (Fig. 2), 
promotes the rapid transfer of phospholipids into the air-liquid interface and 
repetitively stabilises compressed lipid/peptide films. There has been some 
controversy as to the real disposition of this synthetic peptide in surfactant 
membranes and films. Despite the fact that KL4 was originally designed to 
mimic some of the amphipathic peripheral helices in SP-B, it adopted a mainly 
transmembrane orientation in phospholipid membranes, i.e., similar to the 
disposition of the other hydrophobic surfactant protein, SP-C (see below) [93]. It 
is conceivable that KL4 may have not a simple disposition in surfactant 
membranes, but still perturbs phospholipid packing enough to facilitate the 
transit of surface active phospholipids from bilayers into the interface. Once at 
the interface, the orientation of KL4 would have different restrictions to those 
imposed by the bilayers, and it would probably approach the originally 
proposed orientation  [82,94]. At this point, it is important to consider that the 
orientation, the lipid-protein interactions and the potential activity of short 
isolated peptides could differ vastly from the properties that a similar sequence 
may have in the very different structural context of the entire protein fold. 
However, a simple peptide could be an efficient additive as a result of its own 
intrinsic behavior. The simple sequence of the KL4 peptide facilitates an 
affordable synthesis and its availability in large amounts. Surfactant 
preparations such as Surfaxin©, or Lucinactant®, contain a small proportion of 
KL4 in a suspension of DPPC/ POPG/Palmitic acid (PA), and show certain 
efficacy as a replacement surfactant in cases of the respiratory distress 
syndrome in neonates [36]. The availability of this product has made its 
evaluation as a potential treatment for ARDS in adults with ALI possible. 
Treatment with surfactant of the inflamed and injured lungs of these patients 
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has not been possible because of the large amounts of material required to treat 
adults, especially under conditions where an inactivation of surfactant in the 
airways is produced. A lavage of the injured lungs with a diluted solution of 
KL4-containing surfactant has been reported to remove inactivating substances 
and to improve treatment among ARDS patients [95].  
Nevertheless, it is difficult to assume that a peptide with the simple 
sequence of KL4 can really mimic the activities of SP-B, whose amino acid 
sequence is remarkably conserved in the evolution of air-breathing vertebrate 
animals. Indeed, the presence of a fair proportion of palmitic acid is required 
for KL4-containing preparations to sustain the very lowest surface tensions 
under dynamic cycling [96] as discussed above. The need to include palmitic 
acid to ensure proper stability of compressed surfactant films is probably 
related to a lack of sufficient SP-B activity. This is mainly because SP-B has been 
specifically reported to provide high stability to the compressed states of the 
films associated with the lowest surface tensions [78]. Palmitic acid is an 
important component of Survanta, a clinical surfactant obtained from bovine 
lungs, which has a substantially reduced proportion of SP-B [16]. Venticute®, a 
surfactant preparation containing a recombinant form of surfactant protein SP-
C, but not SP-B, also requires palmitic acid for optimal performance [40,43]. In 
contrast, Curosurf, another animal-derived surfactant preparation, produced 
from porcine lung tissue and containing a fair proportion of SP-B, does not 
require the addition of palmitic acid to reproduce pulmonary surfactant 
dynamics either in vitro or in vivo. 
Other synthetic peptides have been designed and tested to find a better 
mimic of the SP-B action. Numerous experiments have shown that peptide SP-
B1-25, with a sequence corresponding to the 25 N-terminal residues of human SP-
B (Fig. 2), can mimic many of the membrane, and monolayer-perturbing 
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properties as well as the surface activity behaviour of the native protein isolated 
from animal lungs and reconstituted in lipid/protein suspensions [33,97-99]. In 
fact, a recent study mapping the main structural and functional determinants in 
the sequence of SP-B has confirmed that the N-terminal moiety of the protein 
contains most of the membrane-perturbing activities required for the protein to 
sustain very low surface tensions in a dynamic compression-expansion in vitro 
model [30]. The behaviour of SP-B1-25 seems to improve significantly if it is 
converted into a dimeric form, d SP-B1-25, in which two copies of the peptide are 
joined by a disulfide bond between the two cysteine 8 residues [32,100]. The 
combined action of several SP-B amphipathic helices is apparently important 
for the protein to act as a bridge that interconnects membranes and interfacial 
films, potentially promoting the formation of surface-associated reservoirs of 
surfactant [78,101].  
Other small cationic proteins, which have the ability to promote the 
exchange of phospholipids between different membranes, have been proposed 
as potential SP-B-mimicking analogs. Indeed, this is the rationale behind the 
inclusion of polymixin as a potentially useful surfactant additive [69]. A slightly 
different strategy was adopted in the design and synthesis of SP-B-inspired 
helical assemblies, which contain not one, but several potential amphipathic 
segments of the protein as they are cross-linked in the native fold via disulfide 
bonds. The so-called Mini-B is a synthetic construct containing the sequences of 
N- and C-terminal segments of SP-B, cross-linked by two disulfides equivalent 
to two of the three intramolecular disulfides in native SP-B [31,102]. Mini-B is 
probably a more faithful mimic of a real structural motif in native SP-B. In 
general terms, all these peptide motifs, based on the structure of SP-B, have 
acceptable biophysical properties when combined with surfactant lipids to be 
potentially useful to develop new therapeutic surfactants. Some of these 
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peptides have shown relatively good antibiotic activities against respiratory 
pathogens [88] which suggests that their combined biophysical and 
microbiocidal action could be highly beneficial in the treatment of injured 
lungs. 
However, the probability that new surfactant preparations containing 
specific synthetic peptides could be extensively used in the treatment of 
respiratory pathologies is low if we consider the real costs of synthesising 
peptides with such a specific sequence in the amounts required. A possible 
alternative, which has been recently considered, is the development of non-
peptidic structures that mimic SP-B activities. Several attempts have been made 
toward designing and characterising SP-B-like peptoids, that is, oligo-N-
substituted glycines which are foldable in amphipathic helical conformations 
[103-105]. Some of these non-natural SP-B analogues show a promising surface 
activity in vitro and are currently being optimised further. The synthesis of 
peptoids would prove only slightly less expensive than producing equivalent 
amounts of regular peptides, but their much lower degradability could permit a 
sustained activity in vivo with a significantly reduced dosage. Extensive studies 
are still required to evaluate the real performance of these chemicals in animal 
models in terms of both physiological efficacy and biological safety. 
A definitive strategy to successfully develop new SP-B-based synthetic 
surfactants will necessarily require an optimisation of the methods to produce 
recombinant versions of the protein in large amounts. The recent production in 
bacteria of a precursor of human SP-B [106] is a promising perspective. 
Cleavage of this recombinant protein may provide considerable amounts of the 
mature SP-B sequence, even if the polypeptide is not properly folded and the 
disulfides are not correctly formed. The experimental evidence available today 
suggests that polypeptides with the SP-B sequence should, in principle, be 
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extractable with organic solvents and susceptible to be reconstituted in 
lipid/protein suspensions with a sufficiently good surface activity. Even if the 
activity of this recombinant protein is not much better than that of the synthetic 
peptides, bacterial production would at least potentially provide an affordable 
way to accumulate the amounts of surfactant required to perform extensive 
research on its potential clinical use. 
 
Structure-function relationships of SP-C 
 
Pulmonary surfactant protein C (SP-C), the smaller of the two hydrophobic 
proteins present in the lung surfactant, constitutes ~1% of surfactant by mass. 
SP-C is important in promoting the spread of the surfactant lipids to the air-
water interface. This protein is synthesised as a propeptide with only one 
transmembrane fragment and a molecular mass of 21 kDa, which adopts a type 
II orientation (i.e., with the N-terminus facing the cytoplasm and the C-
terminus being translocated across the membrane) [107]. Unlike SP-B therefore, 
SP-C is an integral membrane protein in which the transmembrane fragment 
(that which remains in the mature SP-C) serves as both a signal peptide and 
membrane-spanning domain. Mature SP-C is formed by several proteolytic 
steps at both the N-terminal and C-terminal ends of the propeptide, and is 
stored in the lamellar body of alveolar type II cells before being secreted into 
the air space along with phospholipids [108]. The N-terminal region of the 
propeptide (residues 1-23 in the human sequence) is required for intracellular 
sorting and secretion [109], while the C-terminal domain (residues 59-197, or 59-
191 following alternative splicing of the primary transcript [60]), likely plays an 
important role in the folding of the mature peptide [110,111]. The mature SP-C 
is a small (4.2 kDa), very hydrophobic and highly conserved protein (Fig. 3A), 
with a polar N-terminal segment and a C-terminal stretch of aliphatic residues 
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with predominating valine residues. SP-C isolated from bronchoalveolar 
lavages is mostly dipalmitoylated [112]. Palmitoyl chains are attached to 
cysteine residues 5 and 6 (numbering is based on the sequence of the mature 
protein of human origin) of the propeptide before its processing to mature SP-C 
[113] to increase further protein hydrophobicity. An exception to this 
consecutive cysteine pairing is found in several mammals [114], where a 
phenylalanine, substituted as a surrogate for one of the palmitates, is found in 
all cases. Palmitoyl chains are thought to serve as an anchor between the 
interfacial film and the neighbouring associated surfactant layers, thus keeping 
lipids in this fashion which have been squeezed out during the compression of 
the surface film near the interface for rapid insertion upon the next inhalation 
[4,115]. Other characteristics of the mature SP-C sequence are two prolines that 
flank the palmitoylated cysteine residues. Only one exception was seen in the 
recently reported xenopus SP-C gene [116], which codes for a protein with two 
prolines in this region, but not in the position that flanks the aforementioned 
Cys-Phe pair (Fig. 3A). In addition, two positively charged amino acids 
(positions 11 and 12) precede the highly hydrophobic C-terminus of the protein 
in all mammal species that have been sequenced [114]. The two basic residues, 
which probably interact with the head groups of negatively charged 
phospholipids [117], influence the palmitoylation of the propeptide indirectly 
by defining the subcellular localisation of the protein required for 
palmitoylation [113]. Following the two positively charged residues, the mature 
SP-C presents a transmembrane domain consisting of 23 hydrophobic amino 
acids, which is unusually rich in valine residues (Fig. 3). 
The secondary structure of SP-C was initially determined in a lipid 
bilayer using attenuated total reflection Fourier-transform infrared 
spectroscopy [118]. This study found that SP-C molecules are characterised by a 
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high "-helical content, where the helical axis was found to be parallel to the acyl 
chains in lipid bilayers. The " helix was confirmed between residues 9 and 34 
by NMR spectroscopy in organic solvents and in the presence of detergent 
micelles, while the rest of the molecule presented a disordered conformation 
[119,120] (Fig. 4). The helix is 37 Å long, which matches the thickness of a fluid 
DPPC bilayer, consistent with the transmembrane disposition of SP-C in 
membranes. Moreover, assuming that each residue in a "-helical conformation 
covers a length of 1.5 Å, the valine-rich stretch (residues 13-28) is 24 Å long, 
which conveniently matches the estimated 26Å thickness of the acyl-chains in a 
fluid DPPC bilayer [121]. Interestingly, the length of the acyl-chains of a DPPC 
bilayer in the gel phase is 36Å [122], clearly less suitable for a transmembrane 
insertion of the SP-C helix. This fact could be important for the SP-C function 
since a mismatch between the length of the transmembrane fragment and the 
hydrophobic region of its environment could induce segregation and self-
association of the protein in certain surfactant environments [123].  A similar 
hydrophobic mismatch is known to cause phase separation of other peptides 
and lipids [124], and may even affect transmembrane helix packing [125]. In 
lipid monolayers, the helix tilt has been suggested to depend on the surface 
pressure, and is influenced by the presence of the palmitic groups in the SP-C 
molecule [126]. Later, the SP-C helix tilt angle was shown to change from 
approximately 24º to the interface normal in lipid bilayers to approximately 70º 
in mixed monolayer films [127]. This study proposed that SP-C may act as a 
"hydrophobic lever" by maximising its interactions with the lipid acyl-chains 
while simultaneously providing a reasonable molecular mechanism for the 
protein-aided spreading of lipids [127]. However, the relative position of the 
palmitoyl-cysteines in relation to the valine-rich "-helix is still uncertain as they 
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could either be embedded within the same phospholipid bilayer or interact 
with neighbouring bilayers or monolayers. This latter possibility is consistent 
with the previously indicated hypothesis that SP-C might be responsible for an 
association with the interface of materials that had been squeezed out during 
compression to enable subsequent reinsertion. The SP-C helix could switch 
from monolayer into bilayers while maintaining its association with lipids 
during compression. Upon subsequent expansion, the helix could flip back into 
the interface and promote a reincorporation of collapsed phospholipids. 
SP-C isolated from animal lungs has been shown to bind bacterial 
lipopolysaccharide (LPS) with a high affinity [128,129]. It has been proposed 
that this endotoxin-binding activity may be important to keep pro-
inflammatory responses at the alveolar surface under control. Binding of LPS 
would reside in the N-terminal segment of SP-C, although the presence of the 
hydrophobic helix is also apparently important in promoting a proper 
orientation of the N-terminal segment on the surface of phospholipid layers 
[130]. In this sense, SP-C could play an important role in scavenging the 
environmental LPS from pro-inflammatory cascades that could end in 
exacerbated sustained responses. 
In addition to its pronounced hydrophobicity, manipulation and studies 
of SP-C are further complicated by its structural instability. SP-C can transform 
irreversibly from a monomeric " helix into aggregated # sheets [131], which 
form amyloid fibrils [132]. # sheet formation is observed in vitro by the removal 
of the transmembrane domain from the phospholipid environment. SP-C fibrils 
are formed in an organic solution in the absence of lipids, and fibrillation does 
not occur when SP-C is embedded in lipid membranes. In vivo amyloid fibrils 
are observed in patients with pulmonary alveolar proteinosis (PAP) where 
protein aggregates accumulate in the alveoli [132]. Deacylation was found to be 
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another factor that increases the instability of the SP-C " helix [133]. This 
conformational instability is interpreted as being a consequence of the dual 
conformational propensity of certain amino acids depending on their 
environments [134]. 
The SP-C transmembrane fragment is composed of 10-12 valines, 
depending on the species (Fig. 3A), with the other residues being Ile or Leu. 
Valines and isoleucines have !–branched side chains, which makes them prone 
toward ! strand conformation rather than " helices [135]. However, in a lipid 
environment !-branched Val and Ile promote helix formation [136], which 
would explain why the molecule is mainly "-helical in its natural environment. 
 
SP-C-related synthetic surfactants  
Although SP-B appears to have the most important surface-active effect on 
phospholipids, abundant data seem to suggest that a pure SP-C-containing 
surfactant could still possess enough activity to be effective in the treatment of 
surfactant-deficient pathologies. On the other hand, the joint use of SP-C with 
SP-B in surfactant formulations may produce synergistic effects in terms of 
surfactant activities, as well as further lung protection. Based on the functional 
roles summarised above, several SP-C analogues have been designed to be 
included as the main active component in various surfactant preparations. Most 
SP-C analogues have been designed using the known sequence and structure of 
this hydrophobic protein as a template. 
One of the earliest efforts to obtain a synthetic analogue for SP-C was 
performed to gain insight into the structural basis of the molecule [120]. This 
study, using a chemically synthesised N-terminal non-palmitoylated SP-C-
derived peptide (residues 1-17, human sequence), focused on the 
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characterization of the structural features of the protein, in addition to 
questioning the contribution and function of the palmitoyl groups bonded to 
the cysteines. Further studies, using native SP-C, its chemically depalmitoylated 
form and several synthetic analogues lacking the palmitoyl-cysteine residues, 
were analysed to ascertain the secondary structure and biophysical activity. The 
output of these studies demonstrated a correlation between helical content and 
biophysical activity [137]. Synthetic peptides, which showed a lower helical 
content than the native protein, also displayed a lesser ability to accelerate lipid 
spreading at the air-water interface. This led to the idea that analogues, which 
mimic the secondary structure, rather than an exact amino acid sequence, could 
serve as SP-C analogues in synthetic preparations [137]. 
Full-length non-palmitoylated human SP-C analogues and various 
truncated forms of different lengths corresponding to various regions of the 
molecule have been evaluated both in vitro and in a rabbit preterm RDS model 
[138]. The sequence of residues 5-31 or 6-32, which includes the valine-rich 
helical structure in native SP-C, was necessary for biophysical activity. 
However, no data on the secondary structure of this isolated region has been 
reported to date. Given that the formation of a transmembrane "-helix is more 
important than retaining the exact amino acid sequence [137], and that a poly-
valine sequence does not favour helical conformation, several efforts have been 
made to replace the valine-rich region in SP-C with residues with a higher 
helical propensity. SP-C analogues with the valine-rich region replaced with 
leucines, not only folded efficiently into the alpha-helix [139], but also 
accelerated surface spreading at the air-water interface while significantly 
improving dynamic surface activity to function as an excellent surfactant when 
instilled together with lipids in premature rabbit neonates [140]. However, the 
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leucine-rich SP-C derivatives (SP-C(Leu), Fig. 3B) have an intrinsic tendency to 
oligomerise and pose solubility problems when suspended in lipid mixtures 
[139]. The oligomerisation problem was initially circumvented by including 
several lysine residues in the middle of the leucine-rich region (SP-C(SLK) 
peptide, Fig. 3B). The presence of positive charges around the helical 
circumference avoided self-oligomerisation while maintaining helical 
conformation [141]. Surfactant preparations containing the latter peptide 
displayed optimal properties in vitro [141], although in vivo performance was 
probably compromised by complex peptide/membrane interactions involving 
the leucine-rich region [142]. In order to overcome the low in vivo performance 
of the SP-C(SLK) peptide, a derivative form bearing a single lysine residue in 
the N-terminal region of the "-helical segment was more recently designed (SP-
C33, Fig. 3B). This peptide is highly soluble in lipids and does not oligomerise. 
The surfactant preparations based on this molecule increase lung compliance in 
preterm rabbit foetuses to levels similar to those favoured by modified natural 
surfactant preparations that are currently in clinical use [42]. 
The same rationale for synthesising functional SP-C analogues to 
maximise helical conformations while minimising #-sheet conformation leading 
to irreversible peptide aggregation, was followed in a design where the original 
valine residues at the valine-rich region were periodically substituted by 
alanine residues [143]. Alanine is the amino acid with a higher difference 
between "-helical and #-sheet propensities [135], which makes it a suitable 
candidate for preventing the #-sheet aggregation of the synthetic analogues. 
This alanine-containing SP-C-mimicking peptide (SP-C(A), Fig. 3B) was used to 
dope Survanta© (Beractant©), a commercial therapeutic surfactant of natural 
origin, which increased oxygenation in a surfactant-deficient rat model [143]. 
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No structural characterisation of this peptide has been reported to evaluate the 
conformation associated with its optimal activity. 
Recent studies using short synthetic peptides derived from the N-
terminal region of SP-C demonstrate that this region has a high affinity toward 
membrane interfaces, even in the absence of palmitoylated cysteines, and is able 
to produce perturbations in lipid packing and membrane permeability in 
surfactant membranes [144] and interfacial films [145]. It is, therefore, proposed 
that the N-terminal region could play a major role in the ability of SP-C to 
promote interfacial adsorption of phospholipids. 
As for the case of SP-B, non-peptide (peptoids) analogues that mimic 
amino acid sequence patterning and conformation of SP-C have been designed 
[146]. This peptoid adopts a stable helical secondary structure in aqueous and 
organic solvents. Furthermore, it improved the kinetics of lipid adsorption to 
the interface and reduced the degree of film compression required to reach the 
minimum surface tension during cycling in a pulsating bubble surfactometer 
when it was introduced into lipid mixtures at a 10% (w/w) ratio [146]. No data 
on the in vivo performance of these molecules has been published to date. 
Another approach to the synthesis of SP-C analogues has been the use of 
recombinant technology. Initially, a synthetic surfactant based on bacterially 
expressed recombinant SP-C (rSP-C), lacking palmitoyl chains, was found to be 
effective in the treatment of preterm neonates in a rabbit model of RDS [41]. 
There has also been a report about recombinant human SP-C being produced 
with a certain degree of palmitoylation in the baculovirus expression system 
[147]. Nonetheless, more efforts have been made in recent years to optimise 
other bacterial expression systems. In this line, a recombinant 34-amino acid 
human SP-C sequence, altered by the replacement of the cysteine at positions 4 
and 5 with phenylalanines and that of the methionine at position 32 with 
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isoleucine (rSP-C34FF(M32I), Fig. 3B), was used to prepare a synthetic 
surfactant. This synthetic surfactant improved the lung function in preterm 
rabbits and lambs [40], and also in animal models of acute lung injury where 
the effect on oxygenation and histology was studied [39] and compared with 
that of natural or synthetic surfactants [38]. The intratracheal instillation of this 
bacterially-expressed recombinant SP-C-based surfactant displayed no 
significant risk of an anaphylactic shock reaction in a guinea pig model of acute 
lung hypersensitivity [37]. The rationale behind the cysteine$phenylalanine 
replacement in this SP-C variant is that palmitoylation represents an 
insurmountable challenge for bacterial expression machinery, and that the SP-C 
sequence from some animal species has a phenylalanine which replaces one of 
the palmitates [114] (Fig. 3A). In addition, the possibility remains that this 
particular amino acid can mimic, at least partially, the role of palmitoylated 
cysteines owing to the high propensity of the phenylalanine residue to partition 
into the membrane interface [148]. The potential utility of recombinant SP-C 
proteins bearing phenylalanine surrogates is strengthened by its successful use 
in the animal models mentioned above [38-40], and by the favourable behaviour 
reported for Venticute! both in vitro and in vivo. This rSP-C-containing 
surfactant has even been used in trials to treat patients with acute respiratory 
distress syndrome. Survival of these patients did not significantly improve 
upon receiving this surfactant, but the patients who received Venticute© 
displayed a greater improvement in gas exchange in the 24-hour treatment 
period than patients receiving standard therapy [149]. The favourable 
performance exhibited by recombinant SP-C variants harbouring 
phenylalanines instead of palmitoylated cysteines also seems to have a 
structural basis, since the resolution of the structure of a Phe-containing 
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recombinant SP-C by NMR reported no substantial differences when compared 
to the structure of wild-type native palmitoylated SP-C [150]. 
In recent work, we have bacterially overexpressed, purified and tested a 
recombinant SP-C construct in which only phenylalanines are substituted for 
palmitoylated cysteine residues (rSP-C35FF) [28]. Compared to the protein 
purified from porcine lungs, the recombinant SP-C forms improved the transfer 
of the phospholipid molecules into the interface (during adsorption), or out 
from the interfacial film (during compression), probably due to the presence of 
the aromatic residues into the N-terminal region and a possibly better 
preservation of the active conformation of the protein, which suggests new 
possibilities of developing improved therapeutic preparations. The inclusion of 
these recombinant SP-C versions may be important not only to optimise the 
biophysical performance of clinical surfactants under the demanding dynamic 
conditions imposed by the lungs, but also to simultaneously modulate the 
inflammatory state of the respiratory epithelium. 
 
New developments and future perspectives  
Some recent developments suggest potential ways to further improve stability 
and resistance to inhibition of surfactant under the demanding conditions of an 
injured lung. Phospholipase-resistant phospholipid analogs have been 
designed, synthetised and tested as potential components in new clinical 
surfactants, showing promising activities, both in vitro and in vivo [102,151]. 
Supplementation with exogenous surfactant of patients with injured lungs 
requires the availability of enough amounts of surfactants with a reasonable 
resistance to inhibition. In these patients, lung oedema and the triggering of 
pro-inflammatory cascades lead to a markedly reduced activity of the 
endogenous surfactant by different mechanisms including competence of 
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serum proteins to reach the air-liquid interface and degradation of surfactant 
lipids and proteins by lipases and proteases liberated at the alveolar spaces 
[18,152]. The development of new clinical surfactants containing those lipase-
resistant species could enhance the therapeutic potential of surfactant 
treatments in ARDS patients. 
A large perspective for strategy improvements in developing new 
therapeutic surfactants will arise when the appropriate procedures for 
producing large amounts of recombinant human surfactant proteins will have 
been fully established. Human analogues of surfactant protein SP-C produced 
by expression in bacteria are already available [28,41], even though they do not 
have the posttranslational cysteine palmitoylation, exhibited by the native 
protein, isolated from animal lungs. Production of human versions of SP-B, 
which is considered the most important protein in surfactant from a biophysical 
point of view, produced either from its recombinant precursor [4] or from any 
other expression construct in prokaryotic or eukaryotic systems, will enable the 
development of a potentially new generation of SP-B/SP-C containing 
recombinant surfactants. The optimisation of the lipid and protein composition 
in these materials should, in principle, yield therapeutic preparations, which are 
more similar to human surfactant than the clinical surfactants available today, 
and hopefully in amounts which will allow clinical research on adult 
respiratory pathologies with certain possibilities. On the other hand, recent 
studies have been successful in obtaining certain amounts of recombinant 
human SP-A, the main hydrophilic surfactant protein, through expression in 
mammalian cell cultures [153-155]. This recombinant SP-A version exhibits, at 
least in vitro, similar functional properties to the wild-type protein. 
Supplementation of clinical surfactants with recombinant SP-A would 
complement the biophysical activities with immunomodulatory and defence 
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properties provided by the collectin. Either the inclusion of SP-A [156,157] or 
the addition of alternative compounds, such as glycopolymers [18,158,159], may 
represent future potential strategies to enhance surfactant resistance to 
inhibition by serum components, a major factor involved in the pathology of 
acute lung injury. An extensive exploration of the biophysical, antioxidant, anti-
inflammatory and antibiotic properties of surfactant preparations of a variable 
protein and lipid composition, possibly including proteins tailored by the 
genetic manipulation of their sequence in the recombinant expression systems, 
could provide a collection of a la carte therapeutic surfactants specifically 
designed for defined pathophysiological conditions. 
Massive production of surfactant will also open new possibilities in the 
application of surfactant as a more generic tool in respiratory medicine. The 
intrinsic dynamic properties of surfactant to spread rapidly and efficiently 
along the whole respiratory surface make it a promising vehicle to deliver 
drugs into the distal airspaces. The potential for surfactant serving as a gene-
delivery [160,161] or drug-delivery [162,163] agent are already being explored. 
New generation pulmonary surfactant preparations could be optimised to 
maximise drug-carrying properties while maintaining surface dynamics under 
the respiratory context. 
However, some of the most significant developments in relation to 
pulmonary surfactant therapies may yet be unsuspected considering the 
current state of knowledge of the molecular mechanisms associated with 
pulmonary surfactant proteins. Accessibility of recombinant surfactant protein 
production and genetic manipulation will open new ways to delve deeper into 
the understanding of their mechanism of action and into the real role they play 
in the respiratory physiology of all air-breathing animals on Earth. Only then 
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Figure 1. Mature SP-B protein sequences. A) Protein sequence alignment of 
mature SP-B from different species. h, human; p, pig; s, sheep; d, dog; m, 
mouse; r, rat; x, xenopus; sequence alignment was obtained using the BLAST 
service from the SwissProt database. The amino acids are shown in single-letter 
code. The positively and negatively charged residues are marked with a plus 
and a minus symbol respectively on top, and the only tryptophan residue is 
highlighted in italic. Lines connecting the very conserved cysteine residues 
(shown in bold) represent disulfide bonds. B) Sequences of the SP-B analogues 
discussed in the text. 
Figure 2. Structural model of SP-B according to the saposin-like folding and 
the regions of the protein that have inspired SP-B analogues. A) model of the 
SP-B dimer inspired by the structure of NK-lysin (PDB code: 1NKL) as a model 
of the saposin fold. In yellow the side chains of conserved cysteine residues are 
highlighted, and a bridge between them represents a disulfide bond. B) Model 
of the SP-B1-25 peptide. C) Model of SP-B1-25 disulfide-dimer. D) Due to the 
presence of alternating positive charged residues and hydrophobic residues, the 
C-terminal region of SP-B (highlighted with a dotted line box) was used for the 
design of model peptides like KL4 (below). In both models the side chains of the 
positive charged residues (Arg and Lys) are shown. D) Structural model of the 
mini-protein Mini-B, inspired from the N- and C-terminus of SP-B (PDB code: 
2DWF). Disulfide bonds are shown. 
Figure 3. Comparison between sequences of SP- C from different origins and 
sequences of SP-C-derived peptides and recombinant proteins used for 
structural and functional studies. (A) Native SP-C sequence alignment 
highlighting the Cys residues in bold, Phe residues at positions 5 and 6 in italic 
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and Pro residues underlined. h, human; p, pig; r, rabbit; mk, monkey; m, 
mouse; s, sheep; d, dog; mi, mink; x, xenopus (B) Amino acid sequences of 
chemically synthesised peptides and rSP-Cs mentioned in this work. Leu, SP-
C(leu); SLK, SP-C(SLK); 33, SP-C33; Ala, SP-C(Ala); r, rSP-C; r34, rSP-
C34FF(M32I); r35, rSP-C35FF (see the text for details). The same residue code as 
in (A) is used. 
Figure 4. Molecular graphics of SP-C structure. A) Helical region is shown in 
ribbon style, two plamitoylated moieties bound to cysteine 5 and 6 has been 
modelled using MolMol (PDB: 1SPF). B) Model of SP-C structure with free Cys 
residues. C) Model of SP-C structure with the Cys residues mutated to Phe. 
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MiniB         CWLCRALIKRIQAMIPKG                                     GRMLPQLVCRLVLRCS
SPB59-79                                          TLLGRMLPQLVCRLVLRCSM
A









































  FGIPSSPV-LKRLLILLLLLLLILLLILGALLMGL Leu
  FGIPSSPVHLKRLLILKLLLLKILLLKLGALLMGL SLK
    IPSSPVHLKRLKLLLLLLLLLLLLILGALLMGL 33
  FGIPCCPVHLKRLLAVAVAVALAVAVAVGALLMGL Ala
  FGIPCCPVHLKRLLIVVVVVVLIVVVIVGALLMGL r
   GIPFFPVHLKRLLIVVVVVVLIVVVIVGALLIGL r34
  FGIPFFPVHLKRLLIVVVVVVLIVVVIVGALLMGL r35
A
B
20  3010++
20  3010++
Nt
Palmitoyl-
A B
Ct
Cys-6
Cys-5Cys-5
Cys-6
C
Phe-5
Phe-6
